<DOC>
	<DOCNO>NCT00736593</DOCNO>
	<brief_summary>Nexagon™ novel compound promote wound heal temporarily disrupt cellular communication wound site , thereby promote accelerate healing , reduce inflammation pain . This randomize double-blind study ass safety , tolerability clinical effect Nexagon™ apply skin wound create punch biopsy healthy volunteer . 43 healthy , fair-skinned male female age 18-40 enrol . Subjects review 3 month 9 month follow-up safety assessment wind appearance evaluation .</brief_summary>
	<brief_title>A Study Evaluating Nexagon™ Treatment Skin Wounds .</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<criteria>1 . Healthy male female subject . 2 . Fair skin ( Fitzpatrick Classification Level I III ) . 3 . Aged 18 40 year inclusive . 4 . Subjects able comply study procedure , include followup assessment visit . 5 . Subjects willing able give write informed consent take part study . 1 . Subjects pigment skin due increase susceptibility hypertrophic keloid scarring ( Fitzpatrick Classification Level IV VI ) . 2 . Subjects know hypertrophic keloid scar former . 3 . Subjects smoke . 4 . Subjects body mass index great 30 kg/m2 . 5 . Subjects bleed disorder take anticoagulant . 6 . Subjects skin lesion sit chronic currently active skin disorder , would adversely affect heal acute wound involve area examine study . 7 . Subjects take take prescribed drug 30 day prior Day 0 , particular , topical systemic steroid , antiinflammatories , anticoagulant , antiproliferative drug , antibiotic . 8 . Subjects regularly take aspirin , ginseng , gilboa , Alka Seltzer overthecounter medicine complimentary health product affect blood clot process . 9 . Subjects history clinically relevant allergy . 10 . Subjects tattoos , scars abrasion site study . 11 . Subjects clinically significant abnormality follow review prestudy laboratory data physical examination . 12 . Subjects show evidence drug abuse . 13 . Subjects clinically significant mental illness opinion Investigator . 14 . Females currently pregnant breastfeed . Females childbearing potential must commit consistent correct use acceptable method birth control , define protocol . 15 . Subjects past present disease , judge Investigator may affect safety subject outcome study . 16 . Subjects participate clinical study within 30 day prior Day 0 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Wound</keyword>
	<keyword>Healing</keyword>
</DOC>